Dr. Bassem Isaac Zaki, MD

Dr. Zaki practices at Dartmouth Hitchcock Medical Center in Lebanon, New Hampshire, part of Dartmouth-Hitchcock Health.

Dr. Zaki's NPI, 1679599625, was assigned on July 14, 2006. Dr. Zaki holds New Hampshire license 11259.

Dr. Zaki's primary practice is Dartmouth Hitchcock Medical Center, at 1 Medical Center Drive, Lebanon, NH 03756 in Grafton County. The practice phone is (603) 650-5000.

Dr. Zaki's primary practice is Dartmouth Hitchcock Medical Center in Lebanon, New Hampshire, part of Dartmouth-Hitchcock Health. The medical group on file is Dartmouth Hitchcock Medical Center. Dmand AI also links Dr. Zaki to 1 more medical group, named with a free account. Dr. Zaki's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Zaki practices. Vendor and product names are available with a free account.

Radiation oncology is Dr. Zaki's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Zaki is licensed in New Hampshire.

CMS data shows 3,542 Medicare services from Dr. Zaki across 20 procedure codes in 2024, for 232 Medicare patients. Medicare paid $210,032 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 232 Medicare patients who saw Dr. Zaki in 2024. The largest group is 65 to 74, with 120 patients. 75% of them have cancer, and 66% have high blood pressure. 8% are also on Medicaid. Their average risk score is 1.28, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Zaki's median patient age at 70, with 32% women.

In 2024, Dr. Zaki wrote 356 Medicare Part D claims for 91 patients. 100% of them were for generic drugs. CMS names the drug for 335 of them, across 8 drugs with 11 or more claims each, at $3,857 in total drug cost. In 2023, CMS named 177 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 80 out of 100 for Dr. Zaki for performance year 2024, reported through an alternative payment model (APM). Dr. Zaki accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Zaki as offering telehealth.

Dmand AI links 25 papers to Dr. Zaki, published from 2011 to 2023. 2023 was the busiest year, with 4. The most frequent topics are Adenocarcinoma, Pancreatic Neoplasms and Antineoplastic Combined Chemotherapy Protocols. Dr. Zaki has published most often in Am J Clin Oncol. Dr. Zaki's most frequent co-authors are Gregory Harold Ripple, MD, Kerrington David Smith, MD and Richard Joseph Barth, MD.

Dmand AI links Dr. Zaki to 3 clinical trials. 2 are still active or recruiting. Conditions studied include Anal Canal Carcinoma, Anthrax and Anus Neoplasms.

CMS Open Payments shows 11 general payments to Dr. Zaki from 6 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 59% of the total. BTG International, Inc. paid the most, $1,082.